MRI and PET scans: what can we measure in Alzheimer’s patients?
ApoE4 and clusterin: partners in crime in Alzheimer’s synaptic degeneration
The landscape of biomarkers for the management of Alzheimer's disease
What do biomarkers mean for the treatment of Alzheimer’s disease?
Prevention is better than cure: identifying the people who are at risk of Alzheimer’s disease